arrow_back Trending Legislation
Share share

NMOSD Research Support: New Consortium and Funding

This act establishes a national consortium to combat the rare neurological disease NMOSD, which leads to blindness and paralysis. Its aim is to accelerate research into the causes, treatment, and biomarkers of the disease, potentially improving the quality of life for patients and their families. $25 million annually is allocated for this purpose until 2024.
Key points
A National Neuromyelitis Optica Spectrum Disorder Consortium will be established to coordinate research on this rare disease.
The Consortium will provide grants for research, collect data, and develop treatment standards, aiming to find more effective therapies.
The act allocates $25 million annually for fiscal years 2021-2024 to fund these efforts, increasing the chances of progress in combating the disease.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Neuromyelitis Optica Spectrum Disorder Consortium Act
Print number: HR 254
Sponsor: Rep. Lee, Barbara [D-CA-13]
Process start date: 2021-01-11
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about NMOSD Research Support: New Consortium and Funding

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 254.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-01-11.

What are the main provisions?

Key points include:

  • A National Neuromyelitis Optica Spectrum Disorder Consortium will be established to coordinate research on this rare disease.
  • The Consortium will provide grants for research, collect data, and develop treatment standards, aiming to find more effective therapies.
  • The act allocates $25 million annually for fiscal years 2021-2024 to fund these efforts, increasing the chances of progress in combating the disease.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Lee, Barbara [D-CA-13].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Analysis and Potential Impact of HR 254

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health